Biogen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

26.01.17	Biogen Inc. Reports 9% Gain In Q4 Profit (RTTNews)
25.01.17	LogMeIn and Bioverativ Set to Join the S&P MidCap 400; Others to Join S&P SmallCap 600 (PR Newswire)
17.01.17	Biogen To Pay $1.25 Bln For Forward Pharma Intellectual Property - Quick Facts (RTTNews)
13.01.17	Biogen Presents New Data From Phase 3 ENDEAR Study Of SPINRAZA (RTTNews)
11.01.17	Technical Reports on Biotech Stocks -- Biogen, Alnylam Pharma, Cascadian Therapeutics, and Marinus Pharma (PR Newswire)
28.12.16	Biogen, Ionis Get FDA Approval For SMA Drug (RTTNews)
24.12.16	IONS Scripts History, PTLA Gets FDA Date, Strongbridge Slumps, NEOT On Watch (RTTNews)
22.12.16	Revolt PR: The First Millennial Agency (PR Newswire)
20.12.16	Biogen’s Board of Directors Approves Separation of Bioverativ and Declares Special Dividend Distribution of Bioverativ Stock (Businesswire)
20.12.16	Biogen Names Chief Commercial Officer Michel Vounatsos As New CEO (RTTNews)
19.12.16	SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Biogen Inc. To Contact The Firm Before Imminent Lead Plaintiff Deadline (PR Newswire)
12.12.16	Cliffs Natural Resources, Tesla Motors, Biogen, Coca-Cola, and Nordstrom and more offer option-trading opportunities that offer returns of more than 19% (PR Newswire)
09.12.16	Biogen And AbbVie Receive Health Canada Approval Of Once-Monthly ZINBRYTA (RTTNews)
30.11.16	BIIB INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Shareholders of a Class Action Involving Biogen Inc. and a Lead Plaintiff Deadline of December 23, 2016 (PR Newswire)
30.11.16	Research Reports Coverage on Biotech Stocks -- Biogen, BioMarin Pharma, Seattle Genetics, and Grifols (PR Newswire)
07.11.16	Biogen & Ionis: SPINRAZA Meets Primary Endpoint In Phase 3 Study - Quick Facts (RTTNews)
31.10.16	BIIB To Face FDA, It's A Thumb Down For REGN, STJ Meets Trial Goal (RTTNews)
28.10.16	Biogen Says FDA Accepts Its NDA For Nusinersen (RTTNews)
26.10.16	Biogen Inc. Q3 Profit Rises 10% (RTTNews)
15.09.16	Biogen Reveals Positive Result For Phase 3 Trial Of Zinbryta In MS Patients (RTTNews)
15.09.16	New Data Presented at ECTRIMS Reinforce Efficacy of ZINBRYTA™ (Daclizumab) and Support Long-Term Safety Profile (Businesswire)
14.09.16	Biogen Reveales Efficacy, Safety Data For Tecfidera In MS Trials (RTTNews)
14.09.16	New Data Affirm Strong Efficacy and Well-Characterized Safety Profile of TECFIDERA® in Both Clinical Studies and Real-World Setting (Businesswire)
31.08.16	Nature Publishes Results from Pre-Clinical Research and Phase 1b Study of Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab (Businesswire)
09.08.16	Biogen Says Bioverativ As Name Of New Hemophilia-Focused Company (RTTNews)
09.08.16	Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company (Businesswire)
05.08.16	The Race To Cure Spinal Muscular Atrophy (RTTNews)
03.08.16	WSJ : Biogen Draws Takeover Interest From Rival Drugmakers (RTTNews)
01.08.16	Biogen, Ionis: Nusinersen Meets Primary Endpoint At Interim Analysis Of Trial (RTTNews)
21.07.16	Biogen Sees FY16 EPS Above View; CEO To Resign; To Buy Back $5 Bln Shares (RTTNews)
21.07.16	Biogen Inc. Q2 Profit Advances 15% (RTTNews)
18.07.16	The World's Top Green Companies (RTTNews)
18.07.16	Biogen and Sobi to Showcase Long-Term Efficacy and Safety Data from Extended Half-Life Hemophilia Therapies at World Federation of Hemophilia 2016 World Congress (Businesswire)
18.07.16	Biogen: SB5 Accepted For Review By EMA - Quick Facts (RTTNews)
18.07.16	SB5, An Adalimumab Biosimilar Referencing Humira®, Accepted for Review by European Medicines Agency (Businesswire)
05.07.16	Biogen And AbbVie's Once-Monthly ZINBRYTA Approved In EU To Treat MS (RTTNews)
05.07.16	Biogen and AbbVie’s Once-Monthly ZINBRYTA™ (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis (Businesswire)
21.06.16	Biogen Names Paul McKenzie Executive Vice President, Pharmaceutical Operations & Technology (Businesswire)
09.06.16	Biogen : Data Shows Safety And Efficacy Of Anti-TNF Biosimilars Portfolio (RTTNews)
09.06.16	New Data Presented at the Annual European Congress of Rheumatology (EULAR 2016) Demonstrate Safety and Efficacy of Biogen’s Anti-TNF Biosimilars Portfolio (Businesswire)
08.06.16	ALDX Expects Data In Q3, CATB Tumbles On Study Data, Teva Gets FDA Panel Nod (RTTNews)
07.06.16	Biogen Says Opicinumab Missed Primary Endpoint; Stock Falls (RTTNews)
07.06.16	Biogen Reports Top-Line Results from Phase 2 Study of Opicinumab (Anti-LINGO-1) in Multiple Sclerosis (Businesswire)
01.06.16	Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Accepted into European Medicines Agency’s PRIME Program (Businesswire)
31.05.16	Biogen Gets Positive Opinion From CHMP On Tysabri - Quick Facts (RTTNews)
31.05.16	Biogen Receives Positive CHMP Opinion for TYSABRI® (Natalizumab) Use in Highly Active RRMS Patients with Inadequate Response to Prior MS Therapy (Businesswire)
30.05.16	FLIXABI, Biogen Infliximab Biosimilar Referencing Remicade, Approved In EU (RTTNews)
30.05.16	FLIXABI®, Biogen’s Infliximab Biosimilar Referencing Remicade®, Approved in the European Union (Businesswire)
30.05.16	AZN's Falcon Hits Goal, FDA Approves MS Drug, CANF Awaits Data In June (RTTNews)
28.05.16	AbbVie, Biogen: FDA Approves Once-Monthly ZINBRYTA For Multiple Sclerosis (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Swiss Re	151.05	1.48 %	K V
Swiss Life Hldg	841.60	1.03 %	K V
Zurich Insur Gr	591.40	0.92 %	K V
Geberit	587.40	0.79 %	K V
UBS Group	25.45	0.63 %	K V
Swisscom	545.50	-0.46 %	K V
Sika	208.20	-0.53 %	K V
Alcon	80.68	-0.62 %	K V
CieFinRichemont	145.40	-0.82 %	K V
Novartis	92.93	-1.36 %	K V

mehr

07:28		EVOTEC-Aktie: Operatives Ergebnis mehr als halbiert
02.05.25		Amgen-Aktie tiefer: Amgen verdient dank starker Nachfrage überraschend viel
02.05.25		DAX 40-Titel Bayer-Aktie: So viel hätten Anleger mit einem Investment in Bayer von vor 10 Jahren verloren
30.04.25		Was Analysten von der Bayer-Aktie erwarten
30.04.25		EVOTEC SE-Aktie: Das sind die Analysten-Einstufungen des vergangenen Monats
30.04.25		April 2025: Experten empfehlen KWS SAAT SE-Aktie mehrheitlich zum Kauf
30.04.25		Sartorius vz-Aktie: Experten empfehlen Sartorius vz im April mehrheitlich zum Kauf
29.04.25		DAX 40-Wert Sartorius vz-Aktie: So viel Verlust hätte ein Sartorius vz-Investment von vor einem Jahr eingefahren

07:28

EVOTEC-Aktie: Operatives Ergebnis mehr als halbiert

02.05.25

Amgen-Aktie tiefer: Amgen verdient dank starker Nachfrage überraschend viel

02.05.25

DAX 40-Titel Bayer-Aktie: So viel hätten Anleger mit einem Investment in Bayer von vor 10 Jahren verloren

30.04.25

Was Analysten von der Bayer-Aktie erwarten

30.04.25

EVOTEC SE-Aktie: Das sind die Analysten-Einstufungen des vergangenen Monats

30.04.25

April 2025: Experten empfehlen KWS SAAT SE-Aktie mehrheitlich zum Kauf